Bioavailability of Insulin Administered in Duodenum

University of Aarhus12 enrolled

Overview

A study of the bioavailability of insulin after infusion in the duodenum in healthy volunteers.

METHODOLOGY All subjects will be admitted fasting to the Clinical Trial Unit at Århus Community Hospital at 8 a.m. A Gastrointestinal tube will be placed in Duodenum distal to papilla Vaterii with a pH of approximately 7.0 as measured by the pH meter distal in the tube. An indwelling catheter for glucose infusion (20 %) in cases of hypoglycaemia will be placed in an antecubital vein. In the contralateral anticubital vein a catheter will be placed for blood sampling. All subjects will have 4 tests with duodenal infusion of the insulin Aspart solution. The first 4 volunteers will receive 4 doses of insulin Aspart solution in 1 ml (150, 300, 600 and 1000 IU) with 3-6 hours apart. Blood sampling for Insulin Aspart, total insulin, and glucose (Beckmann apparatus) will be done every 10 minutes the first two hours, and then every 20 minutes. When final the subjects will receive a meal before leaving the hospital. Based on data from the pilot a dose will be determined for the remaining 8 subjects. These will then based again on results from the pilot on two separate study days receive 4 infusions with 3-6 hours split. Two infusions will be at pH 7 and two infusions will be more proximal at a pH of 5.5 (two different insulin concentrations but the same dose given at the two places in Duodenum). Frequency and interval of blood sampling in the second part will be determined by results from the pilot study. For comparison with the clinical situation and estimation of bioavailability all subjects will receive a subcutaneous and an intravenous (iv) bolus injection of 6 IU of insulin Aspart. The iv injection will be followed by blood sampling for three hours as above, but every 5 minutes the first two hours, and the sc injection will be followed by blood sampling for three hours as above, but again with 10 minutes interval the first two hours.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Diabetes Mellitus

Interventions

Insulin AspartDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent * Healthy Volunteers * Age \>18 - \< 50 years * BMI 18-30 kg/m2 Exclusion Criteria: * Any history of gastrointestinal or endocrine disorders (e.g. diabetes mellitus) * pregnancy or nursing * suspected or known allergy towards the drug * Participation in other research trials within 3 months before the study

Locations (1)

Medical Department M

Aarhus, Aarhus, Denmark

Outcomes

Primary Outcomes

To define the bioavailability of a solution of insulin Aspart infused in the Duodenum

Secondary Outcomes

Evaluate pharmacokinetics of insulin following duodenal administration

Evaluate intra- and intersubjects variation in pharmacokinetic

Evaluate pharmacodynamics of insulin

To assess any safety issues

Explore any influence of PH/ insulin concentration on PK /PD parameters

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.